Sign Out
Silver sulfadiazine (SILVEDERMA) is contraindicated in patients who are hypersensitive to sulfonamides or to any other component of the preparation.
Sulfonamide treatment is usually contraindicated in premature or newborn infants during the first 2 months of life because of the risk of producing kernicterus; for the same reason, they are generally contraindicated in women approaching term and in breast-feeding mothers.
It is advised not to use Silver sulfadiazine (SILVEDERMA) cream in patients sensitive to sulfonamides and in pregnant women. However, due to the hazards of sepsis in severe burns, the use of silver sulfadiazine in such patients must be determined individually.
